Drug intelligence / Profile preview

Rovanyl

Development stage: Unknown
Lead developer: Ingalfarma
Modality: Small Molecules
Administration: Topical

Overview

Rovanyl (also known as PGR-U) is a pharmaceutical product under development by Ingalfarma for the treatment of periodontitis. It is currently in Phase 2 clinical development. The drug is part of Ingalfarma's innovation pipeline focused on oral health and specialty pharma, aiming to provide local treatment for inflammatory periodontal conditions. Specific details regarding its molecular target or chemical composition are not publicly disclosed, but it is positioned as a clinical-stage candidate following the company's successful marketing of other oral care products like Dentoxol. It is intended for local or topical application within the oral cavity to manage periodontal disease.

Brand names: Rovanyl
Other names: PGR-U

Beyond the preview

Go deeper on Rovanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rovanyl.

Explore the full profile